Business Context and Reporting Period
This Form 8-K Current Report was filed by Bio-Rad Laboratories, Inc. on March 20, 2024. The filing discloses the appointment of a new senior executive officer effective April 15, 2024.
Key Financial Metrics
This filing does not contain operational financial results such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The financial data provided relates exclusively to the compensation package for the newly appointed Chief Financial Officer:
- Annual Base Salary: $600,000
- Target Cash Bonus (2024): 75% of eligible earnings
- Restricted Stock Units (RSUs): Valued at $1,450,000 (to be granted within 60 days of hire)
- Long-Term Incentive Plan Target (2024): $2,000,000
- Relocation Credit: $20,000
- Severance Provision: 18 months of base salary if terminated without good cause
Material Changes
The primary material change reported is the appointment of Roop K. Lakkaraju as Executive Vice President and Chief Financial Officer (CFO), effective April 15, 2024. Mr. Lakkaraju joins the company from Benchmark Electronics, where he served as EVP and CFO from 2018 to 2024.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, market outlook, or discussion of operational risks. The document focuses solely on the terms of the new employment agreement and the background of the incoming CFO. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the effective start date of the new CFO (April 15, 2024) and the transition plan for the outgoing CFO.
- Review the attached Employment Offer Letter (Exhibit 10.1) for specific performance metrics tied to the bonus and long-term incentives.
- Confirm the timing of the RSU grant relative to the hire date to assess immediate dilution impact.
- Check subsequent filings for the departure details of the previous CFO.